抗凝固薬市場：投与経路、抗凝固薬、薬剤クラス別、用途別-2025～2030年の世界予測

抗凝固薬市場は、2023年に402億米ドルと評価され、2024年には442億4,000万米ドルに達すると予測され、CAGR 10.14％で成長し、2030年には790億7,000万米ドルに達すると予測されています。

抗凝固薬は、脳卒中、心臓発作、深部静脈血栓症などの症状を引き起こす可能性のある血栓形成を予防する薬剤クラス別です。抗凝固薬は、血栓性疾患の管理と予防に極めて重要であるため、医薬品、バイオテクノロジー、医療の各セグメントにまたがっています。これらの薬剤の必要性は、心血管疾患の有病率の増加や、そのような状態に陥りやすい高齢者の増加により生じています。抗凝固薬の用途は、病院、クリニック、在宅医療に及び、治療と予防の両方のレジメンで使用されます。最終用途の範囲には主に医療プロバイダーが関与しており、研究機関と製薬メーカーは開発と流通における重要な利害関係者です。主要成長要因としては、ドラッグデリバリーシステムの進歩、血栓症に対する意識の高まり、ワルファリンのような従来の治療法に代わる新規経口薬（NOAC）の採用などが挙げられます。この市場はまた、アジア太平洋の新興市場や標的特異的な抗凝固薬のような技術革新に後押しされ、有利な機会をもたらしています。

しかし、市場成長はNOACの高コスト、厳しい規制枠組み、慎重な患者モニタリングが必要な出血性合併症のリスクなどの課題に直面しています。解毒剤の開発は依然として重大な制限であり、NOACの普及に影響を及ぼしています。副作用の少ない、より安全で効果的な薬剤の開発に向けて、技術革新と研究が進められています。薬理遺伝学的知見を用いた薬剤療法の個別化は、ビジネス成長のための有望なフロンティアです。市場の競争は激化しており、主要企業は研究開発に多額の投資を行っています。その結果、患者の転帰を改善するために実世界のデータと人工知能を利用することは、将来的な探求のためのエキサイティングな領域を提示し、最終的には抗凝固薬の治療指標を洗練させ、課題を軽減することを目指します。

市場力学：急速に進化する抗凝固薬市場の主要市場洞察を公開

抗凝固薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 静脈血栓塞栓症と心血管障害の有病率の増加
  • 抗凝固スチュワードシッププログラムの増加
  • 新規経口薬の受け入れ拡大抗凝固薬
• 市場抑制要因
  • 投薬量と臨床承認に関する厳しい規制
• 市場機会
  • 新規抗凝固治療の採用と研究開発投資の増加
  • 抗凝固制御を予測するためのAIとMLの利用
• 市場課題
  • 経口薬の使用に伴う副作用と合併症抗凝固薬

ポーターのファイブフォース：抗凝固薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗凝固薬市場における外部からの影響の把握

外部マクロ環境要因は、抗凝固薬市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：抗凝固薬市場における競合情勢の把握

抗凝固薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：抗凝固薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗凝固薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：抗凝固薬市場における成功への道筋を描く

抗凝固薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 静脈血栓塞栓症と心血管疾患の罹患率の増加
    • 抗凝固療法管理プログラムの増加
    • 新規口頭発表の受け入れの増加抗凝固薬
  • 抑制要因
    • 薬剤の投与量と臨床承認に関する厳格な規制
  • 機会
    • 新規抗凝固療法の採用と研究開発投資の増加
    • AIとMLを活用した抗凝固制御の予測
  • 課題
    • 経口投与に伴う副作用と合併症抗凝固薬
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 抗凝固薬市場：投与経路別

• イントロダクション
• 注射抗凝固薬
• 経口抗凝固薬

第7章 抗凝固薬市場：抗凝固薬別

• イントロダクション
• ベトリキサバン
• ダビガトラン
• エドキサバンまたはリバーロキサバン
• エリキス

第8章 抗凝固薬市場：薬剤クラス別

• イントロダクション
• DTIs
• 因子XA阻害剤
• ヘパリン
• ビタミンK拮抗薬

第9章 抗凝固薬市場：用途別

• イントロダクション
• 心房細動と心臓発作
• 深部静脈血栓症
• 肺塞栓症
• 脳卒中

第10章 南北アメリカの抗凝固薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の抗凝固薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの抗凝固薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Akebia Therapeutics, Inc.
• Aspen Pharmacare Holdings Limited
• AstraZeneca PLC
• Athenex, Inc.
• Bayer AG
• C.H. Boehringer Sohn AG & Ko. KG
• Eisai Co., Ltd.
• Eli Lilly and Company
• Johnson & Johnson
• LEO Pharma A/S
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. ANTICOAGULANTS MARKET RESEARCH PROCESS
• FIGURE 2. ANTICOAGULANTS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTICOAGULANTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTICOAGULANTS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY BETRIXABAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY EDOXABAN OR RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ELIQUIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DTIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION & HEART ATTACK, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTICOAGULANTS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 40. CANADA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. CANADA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. CHINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 62. CHINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. CHINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. INDIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 66. INDIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. INDIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. ITALY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 135. ITALY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. ITALY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. POLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 151. POLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 152. POLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. QATAR ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 155. QATAR ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 156. QATAR ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 194. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023

The Anticoagulants Market was valued at USD 40.20 billion in 2023, expected to reach USD 44.24 billion in 2024, and is projected to grow at a CAGR of 10.14%, to USD 79.07 billion by 2030.

Anticoagulants are a class of drugs that prevent blood clot formation, which could lead to conditions such as stroke, heart attack, and deep vein thrombosis. The scope of anticoagulants spans across pharmaceuticals, biotechnology, and healthcare sectors as they are crucial in managing and preventing thrombotic disorders. The necessity of these drugs arises due to the increasing prevalence of cardiovascular diseases and the growing geriatric population, who are more prone to such conditions. The application of anticoagulants extends to hospitals, clinics, and homecare settings, where they are used in both therapeutic and preventive regimens. The end-use scope predominantly involves healthcare providers, whereas research institutions and pharmaceutical manufacturers are crucial stakeholders in the development and distribution. Key growth factors include advancements in drug delivery systems, increasing awareness about thrombotic conditions, and the adoption of novel oral anticoagulants (NOACs) which offer an alternative to traditional therapies like warfarin. This market also presents lucrative opportunities, propelled by emerging markets in Asia-Pacific and technological innovations like target-specific anticoagulants.

However, market growth faces challenges like the high cost of NOACs, stringent regulatory frameworks, and the risk of bleeding complications, which necessitate careful patient monitoring. The development of antidotes remains a critical limitation, affecting the widespread adoption of NOACs. Innovation and research are being directed toward the creation of safer and more effective anticoagulants with fewer side effects. Personalization of drug therapy using pharmacogenetic insights represents a promising frontier for business growth. The nature of the market is increasingly competitive, with significant investments in R&D from leading pharmaceutical companies. Consequently, the use of real-world data and artificial intelligence to improve patient outcomes presents an exciting area for future exploration, ultimately aiming to refine the therapeutic index of anticoagulants and mitigate their challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anticoagulants Market

The Anticoagulants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of venous thromboembolism and cardiovascular disorders
  • Rising number of anticoagulation stewardship programs
  • Increasing acceptance of novel oral anticoagulants
• Market Restraints
  • Stringent regulations related to drug dosage and clinical approvals
• Market Opportunities
  • Introduction of novel anticoagulation therapeutics and increasing R&D investments
  • Use of AI and ML to predict anticoagulation control
• Market Challenges
  • Side-effects and complications associated with the usage of oral anticoagulants

Porter's Five Forces: A Strategic Tool for Navigating the Anticoagulants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anticoagulants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anticoagulants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anticoagulants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anticoagulants Market

A detailed market share analysis in the Anticoagulants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anticoagulants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anticoagulants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anticoagulants Market

A strategic analysis of the Anticoagulants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulants Market, highlighting leading vendors and their innovative profiles. These include Akebia Therapeutics, Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Athenex, Inc., Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, Eisai Co., Ltd., Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulants Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Route of Administration, market is studied across Injectable Anticoagulants and Oral Anticoagulants.
• Based on Anticoagulant Drug, market is studied across Betrixaban, Dabigatran, Edoxaban or Rivaroxaban, and Eliquis.
• Based on Drug Class, market is studied across DTIs, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists.
• Based on Application, market is studied across Atrial fibrillation & Heart Attack, Deep Vein Thrombosis, Pulmonary Embolism, and Stroke.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of venous thromboembolism and cardiovascular disorders
    • 5.1.1.2. Rising number of anticoagulation stewardship programs
    • 5.1.1.3. Increasing acceptance of novel oral anticoagulants
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations related to drug dosage and clinical approvals
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of novel anticoagulation therapeutics and increasing R&D investments
    • 5.1.3.2. Use of AI and ML to predict anticoagulation control
  • 5.1.4. Challenges
    • 5.1.4.1. Side-effects and complications associated with the usage of oral anticoagulants
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anticoagulants Market, by Route of Administration

• 6.1. Introduction
• 6.2. Injectable Anticoagulants
• 6.3. Oral Anticoagulants

7. Anticoagulants Market, by Anticoagulant Drug

• 7.1. Introduction
• 7.2. Betrixaban
• 7.3. Dabigatran
• 7.4. Edoxaban or Rivaroxaban
• 7.5. Eliquis

8. Anticoagulants Market, by Drug Class

• 8.1. Introduction
• 8.2. DTIs
• 8.3. Factor XA Inhibitors
• 8.4. Heparin
• 8.5. Vitamin K Antagonists

9. Anticoagulants Market, by Application

• 9.1. Introduction
• 9.2. Atrial fibrillation & Heart Attack
• 9.3. Deep Vein Thrombosis
• 9.4. Pulmonary Embolism
• 9.5. Stroke

10. Americas Anticoagulants Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Anticoagulants Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Anticoagulants Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Akebia Therapeutics, Inc.
• 2. Aspen Pharmacare Holdings Limited
• 3. AstraZeneca PLC
• 4. Athenex, Inc.
• 5. Bayer AG
• 6. C.H. Boehringer Sohn AG & Ko. KG
• 7. Eisai Co., Ltd.
• 8. Eli Lilly and Company
• 9. Johnson & Johnson
• 10. LEO Pharma A/S
• 11. Novartis AG
• 12. Pfizer Inc.
• 13. Sanofi S.A.
• 14. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• 15. Teva Pharmaceutical Industries Ltd.
• 16. Viatris Inc.